Benefits
Highest GLA Concentration of Plant Oils
Distinguishes borage from evening primrose (~9% GLA) and black currant (~15% GLA). Lower volume of borage oil needed for equivalent GLA dose. This is a statement about composition rather than a demonstrated health benefit. It means fewer capsules for the same GLA, not a better clinical result: no trial has shown borage oil to outperform evening primrose or black currant oil on any health outcome, and the one trial that compared borage seed oil head to head with fish oil in rheumatoid arthritis found no difference between them.
Rheumatoid Arthritis Adjunct
This is the best supported use and also the narrowest. Two placebo controlled trials in people with active rheumatoid arthritis reported reduced joint tenderness, swelling and morning stiffness: 37 patients on 1.4 g/day GLA from borage seed oil for 24 weeks, and 56 patients on 2.8 g/day GLA given as the purified free fatty acid for 6 months. A later 18 month trial in 150 patients compared borage seed oil, fish oil and the two combined; all three groups improved and none beat the others, but there was no placebo arm, so that trial cannot show the oil caused the improvement. A Cochrane review of herbal treatments for rheumatoid arthritis rated the pooled evidence for GLA oils as moderate for relieving pain and disability, while noting more adverse events on GLA than on placebo. Three limits matter. All of this work traces back to one research group, so none of it has been independently replicated. The doses correspond to roughly 6 to 12 g of oil a day, several times a standard 1000 mg softgel. And rheumatoid arthritis is a diagnosed autoimmune disease managed with prescription drugs: in the largest of these trials patients stayed on their usual arthritis medication at stable doses, so what was tested was borage oil added to standard treatment, never a substitute for it. The trial authors themselves wrote that GLA is not approved to treat any condition and should not be viewed as therapy for any disease.
Atopic Dermatitis / Eczema (Not Supported)
Earlier trials suggested benefit; larger systematic review of 27 trials found GLA (from borage and evening primrose) not effective for atopic dermatitis. Current consensus: no benefit despite long standing folk use. The Cochrane authors went further and judged the confidence intervals narrow enough that further eczema trials would be hard to justify. The two borage eczema trials cited on this page point the same way: a 160 patient, 24 week study found no overall efficacy on its primary outcome, and a 118 infant prevention trial found no significant effect on whether atopic dermatitis developed. Where borage oil does have measurable skin data is a different outcome in different people, namely dryness and barrier function in adults who do not have eczema. A 12 week placebo controlled study reported less water loss through the skin and less roughness and scaling, and a small uncontrolled study in older adults reported fewer complaints of dry skin. Both are small, neither has been replicated, and no trial has measured hair or nails at all.
Premenstrual Syndrome (Not Supported)
This is the weakest claim on the page and the evidence actually points the other way. Nearly all of it comes from evening primrose oil rather than borage, and the better trials are null: a review of the premenstrual syndrome trials concluded evening primrose oil is of little value, a 555 woman multicenter trial found GLA no better than placebo fatty acids for cyclic breast pain, and a 120 woman trial found evening primrose oil gave no clear benefit over control oils. No trial has tested borage oil itself for premenstrual symptoms. Treat this as an unsupported traditional use.
Diabetic Neuropathy (One Unreplicated Trial)
One multicentre trial in 111 people with mild diabetic neuropathy reported that 480 mg/day of GLA over a year moved all 16 nerve function and sensory measures in a more favourable direction than placebo, 13 of them significantly. That result has not been replicated in the decades since, the GLA was given as capsules rather than as borage oil, and no product built on it entered routine clinical use. Alpha lipoic acid has more consistent evidence for this indication. Diabetic neuropathy is a diagnosed complication of diabetes that needs medical management, so treat this as a historical research finding rather than a reason to self treat.
Mechanism of action
GLA → DGLA → PGE1 Anti-Inflammatory Pathway
GLA (gamma-linolenic acid) is metabolized via elongase to DGLA (dihomo-gamma-linolenic acid), which produces series-1 prostaglandins (PGE1) — anti-inflammatory, anti-platelet, vasodilatory. Distinguishes from arachidonic acid pathway producing pro-inflammatory PGE2. This is the biochemical rationale for the anti-inflammatory claims rather than evidence for them: the same pathway is why the eczema trials were run in the first place, and those trials were null.
Bypass Delta-6 Desaturase Limitation
Conversion of LA to GLA requires delta-6 desaturase — limited in: aging, diabetes, alcohol use, deficiency states. Direct GLA supplementation bypasses this conversion bottleneck. Theoretical advantage in those with reduced conversion capacity.
Skin Barrier Lipid Support
GLA contributes to skin barrier lipid composition. This is the one skin idea with supporting human measurements: oral supplementation lowered water loss through the skin and improved roughness and scaling in adult women over 12 weeks, and reduced complaints of dry skin in older adults. Those studies are small, one of them had no placebo group, and the same mechanism failed to produce any benefit in the eczema trials.
Cytokine Modulation
GLA modulates pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) via DGLA-derived eicosanoids and direct effects.
Clinical trials
Clinical trial of borage oil GLA (1.4 g GLA/day) vs placebo in 37 RA patients for 24 weeks.
37 RA patients.
GLA reduced tender joint count by 36 percent and swollen joint count by 28 percent versus placebo, while the placebo group showed no change or worsened, and no patient withdrew because of adverse effects. Context matters: this is a single trial of 37 people, run in the rheumatology clinic of a university hospital in patients already under specialist care, and the 1.4 g/day GLA dose corresponds to roughly 6 g of borage oil daily, six times a standard 1000 mg softgel. A later and larger trial from the same research group kept patients on their usual arthritis drugs at stable doses, which is how this should be read: an addition to standard treatment, never a replacement for DMARDs or biologics. The authors closed by writing that GLA is not approved for the treatment of any condition and should not be viewed as therapy for any disease.
Evidence review/pooled analysis of 27 clinical trials of borage and evening primrose oil for atopic dermatitis.
1,596 participants pooled across 27 randomized trials, 19 of evening primrose oil and 8 of borage oil.
GLA not effective for atopic dermatitis. Despite long folk use, clinical trial evidence does not support benefit. Notable example of folk medicine claims not surviving rigorous evaluation.